BCRX: Options Signal Clashes With Rising Short Book

BioCryst Pharmaceuticals is sending conflicting signals. Short sellers are rebuilding aggressively. Options traders are betting the other way at a year-low intensity.

The gap between those two camps has widened sharply this week.

Shorts Keep Building, Cheaply

Short interest stands at 20.4% of free float — up 15.2% in a single week. That is one of the heavier short loads in small-cap biotech. The ORTEX short score has risen to 68.4, up from 63.6 two weeks ago.

What makes this unusual is the cost. Borrowing BCRX now costs just 0.51% annually — down 87% over the past week. A month ago it sat near 4.4%. Shorts are piling in at the cheapest rate since May.

Availability sits at 549%. There are roughly 5.5 shares available to borrow for every one currently lent out. The lending pool is well-supplied. New shorts face no friction.

This looks like fresh directional conviction, not a squeeze-driven scramble.

Options Tell the Opposite Story

The put/call ratio hit 0.104 on June 26 — the lowest reading in 52 weeks. That is 2.6 standard deviations below the 20-day mean of 0.226. Call volume is overwhelming put volume by roughly 10:1.

Options traders are positioned for upside. Short sellers are positioned for downside. Both camps are leaning harder into their views simultaneously.

The stock is up 10.6% over the past week and 17.4% over the past month, trading near $9.94. That move may itself be driving both signals — shorts adding to fading rallies, options buyers chasing the momentum.

What the Institutions Are Doing

Institutional holders are broadly adding. BlackRock increased its position by 1.5 million shares in its most recent filing, now holding 8.9% of shares. State Street added 1.1 million shares. Dimensional Fund Advisors added 1.4 million.

Analyst targets remain well above the current price. Citizens raised its target to $28 in May. Wedbush holds $21. Needham sits at $16. The mean target across the coverage universe is $21.50 — more than double the current price.

Insiders, however, have been net sellers. The Chief Legal Officer sold $596,000 worth of shares in May. A director sold $2.6 million in March. Net insider selling over 90 days totals roughly $5.2 million.

Earnings are due August 5.

Data Summary

• Short interest: 20.4% of free float, +15.2% week-on-week
• Cost to borrow: 0.51%, down 87% over one week
• Availability: 549% — loose lending market, no borrow stress
• Put/call ratio: 0.104 — 52-week low, 2.6 standard deviations below mean
• ORTEX short score: 68.4, up from 63.6 two weeks ago
• Price: $9.94, +10.6% past week, +17.4% past month
• Next earnings: August 5, 2026